NCT05271916View on ClinicalTrials.gov

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

October 13, 2022

Primary Completion Date

January 1, 2025

Study Completion Date

May 1, 2027

Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
DRUG

Dacomitinib+Anlotinib

The dose of each drug in the combination Decomitinib and Anlotinib will be escalated or de-escalated until the recommended phase II dose (RP2D) is reached. Patients will then be treated with RP2D orally once a day.

DRUG

Dacomitinib

Dacomitinib orally on a continuous daily basis at a starting dose of 45 mg once a day until progressive disease.

Trial Locations (1)

200000

RECRUITING

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Chest Hospital

OTHER